Most Read Articles
Pearl Toh, 02 Sep 2020
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.

Weight-loss surgery helps resolve nonalcoholic steatohepatitis

26 Jun 2020

Bariatric surgery may lead to the resolution of nonalcoholic steatohepatitis (NASH) with a sustained reduction in fibrosis over 5 years, as shown in a study.

Researchers followed for 5 years a total of 180 severely obese patients (mean age, 46.7 years; median fibrosis score, 2) with biopsy-proven NASH who underwent bariatric surgery (66.1 percent had gastric bypass). Three patients died from non-liver-related causes: two from surgical complications within the first month after surgery and one from cardiac dysfunction at the 4-year follow-up.

Liver biopsies were obtained from 125 of 169 patients (76 percent) in the first year of follow-up and from 64 of 94 patients (68 percent) at the fifth year. Histological evaluation was not available in some patients mainly because of biopsy refusal.

At 5 years after weight-loss surgery, 84 percent of patients achieved the primary endpoint of resolution of NASH without worsening of fibrosis. Moreover, fibrosis decreased from baseline in 70.2 percent of patients. It disappeared in biopsy samples from 56 percent of all patients, as well as in samples from 45.5 percent of those with baseline bridging fibrosis.

NASH persistence was predicted by a lack of fibrosis reduction and less weight loss (mean reduction in body mass index, –6.3 vs –13.4 kg/m2 in patients with persistent vs resolved NASH, respectively; p=0.017).

NASH resolution was observed at 1 year post-bariatric surgery in biopsies from 84 percent of patients, with no significant recurrence between 1 and 5 years (p=0.17). Finally, reductions in fibrosis started to occur by 1 year and continued until 5 years (p<0.001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Hepatology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 02 Sep 2020
Proton beam radiotherapy (PBT) was noninferior to radiofrequency ablation (RFA) for local progression-free survival (LPFS) in patients with recurrent hepatocellular carcinoma (rHCC), in addition to showing a tolerable safety profile, according to the APROH trial presented during the 2020 digital ILC.
Elaine Soliven, 11 Sep 2020
Treatment with an FGF19 analogue aldafermin, previously known as NGM282, led to a significantly reduced liver fat content (LFC) in patients with nonalcoholic steatohepatitis (NASH), according to a study presented at ILC 2020.